Page 173 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

89Zr-immuno-PET in a phase I trial REFERENCES
1. Glassman PM, Balthasar JP. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2016;43:427-446.
2. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
3. Lamberts LE, Williams SP, Terwisscha van Scheltinga AGT, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:1491-1504.
4. Jauw YWS, Menke-van der Houven van Oordt CW, Hoekstra OS, et al. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol. 2016;7:131.
5. Maisel D, Birzele F, Voss E, et al. Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage- Mediated Immune Modulatory Effects in a Cancer Xenograft Model. PLoS ONE. 2016;11:e0159716.
6. Orian-Rousseau V, Ponta H. Perspectives of CD44 targeting therapies. Arch Toxicol. 2015;89:3-14.
7. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev
Mol Cell Biol. 2003;4:33-45.
8. Toole BP. Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res.
2009;15:7462-7468.
9. Vugts DJ, Heuveling DA, Stigter-van Walsum M, et al. Preclinical evaluation of 89Zr-labeled anti- CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies. MAbs. 2014;6:567-575.
10. Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, et al. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44- expressing solid tumors. Oncotarget. 2016;7:80046-80058.
11. Verel I, Visser GWM, Boellaard R, Walsum MS, Snow GB, Dongen GAMS van. 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies. J Nucl Med. 2003;44:1271-1281.
12. Perk LR, Vosjan MJWD, Visser GWM, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno- PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250-259.
13. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl- desferrioxamine. Nat Protoc. 2010;5:739-743.
14. Makris NE, Boellaard R, Visser EP, et al. Multicenter harmonization of 89Zr PET/CT performance. J 8 Nucl Med. 2014;55:264-267.
15. Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53:1041-1047.
16. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28:1248-1250.
17. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994;124:71-82.
18. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32:5-265.
19. Perk LR, Visser GWM, Vosjan MJWD, et al. 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab. J Nucl Med. 2005;46:1898-1906.
20. Börjesson PKE, Jauw YWS, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
21. Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, et al. ImmunoPET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors. J Nucl Med. February 2019.
171